Cargando…

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Ni, Xu, Qin, Cui, Wei, Feng, Xiaoying, Gao, Huijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/
https://www.ncbi.nlm.nih.gov/pubmed/36544639
http://dx.doi.org/10.21037/atm-22-4652
_version_ 1784852643191980032
author Kong, Ni
Xu, Qin
Cui, Wei
Feng, Xiaoying
Gao, Huijie
author_facet Kong, Ni
Xu, Qin
Cui, Wei
Feng, Xiaoying
Gao, Huijie
author_sort Kong, Ni
collection PubMed
description BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechanism in AS. METHODS: ApoE(-/-) mice were fed with a high-fat diet (HFD) and intraperitoneally injected with 1, 5, or 10 mg/kg inclisiran. Low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) levels were determined using commercially available kits. Oil Red O staining was applied to detect the aortic plaque area and oil formation. Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to induce cell injuries. Cell death was determined using a Hoechst 33342/propidium iodide (PI) dual-staining assay. Cytotoxicity was measured by lactate dehydrogenase (LDH) activity analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analyses were performed to examine the pyroptosis-related factors. RESULTS: Inclisiran inhibited the levels of LDL-C, TC, and TG, but increased the HDL-C level in the AS animal model. It also significantly inhibited plaque and oil droplet formation in a dose-dependent manner. Moreover, inclisiran markedly inhibited pyroptosis, as evidenced by the decreased levels of cleaved-caspase-1, NOD-like receptor family pyrin domain containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC), gasdermin-D (GSDMD)-N, interleukin (IL)-1β, and IL-18. Furthermore, inclisiran substantially inhibited cell death and cytotoxicity induced by ox-LDL in HUVECs. CONCLUSIONS: Inclisiran exerted an anti-atherosclerotic effect by inhibiting pyroptosis. This study provides a theoretical basis for the therapeutic potential of inclisiran in AS.
format Online
Article
Text
id pubmed-9761140
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-97611402022-12-20 PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis Kong, Ni Xu, Qin Cui, Wei Feng, Xiaoying Gao, Huijie Ann Transl Med Original Article BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechanism in AS. METHODS: ApoE(-/-) mice were fed with a high-fat diet (HFD) and intraperitoneally injected with 1, 5, or 10 mg/kg inclisiran. Low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) levels were determined using commercially available kits. Oil Red O staining was applied to detect the aortic plaque area and oil formation. Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to induce cell injuries. Cell death was determined using a Hoechst 33342/propidium iodide (PI) dual-staining assay. Cytotoxicity was measured by lactate dehydrogenase (LDH) activity analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analyses were performed to examine the pyroptosis-related factors. RESULTS: Inclisiran inhibited the levels of LDL-C, TC, and TG, but increased the HDL-C level in the AS animal model. It also significantly inhibited plaque and oil droplet formation in a dose-dependent manner. Moreover, inclisiran markedly inhibited pyroptosis, as evidenced by the decreased levels of cleaved-caspase-1, NOD-like receptor family pyrin domain containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC), gasdermin-D (GSDMD)-N, interleukin (IL)-1β, and IL-18. Furthermore, inclisiran substantially inhibited cell death and cytotoxicity induced by ox-LDL in HUVECs. CONCLUSIONS: Inclisiran exerted an anti-atherosclerotic effect by inhibiting pyroptosis. This study provides a theoretical basis for the therapeutic potential of inclisiran in AS. AME Publishing Company 2022-11 /pmc/articles/PMC9761140/ /pubmed/36544639 http://dx.doi.org/10.21037/atm-22-4652 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Kong, Ni
Xu, Qin
Cui, Wei
Feng, Xiaoying
Gao, Huijie
PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
title PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
title_full PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
title_fullStr PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
title_full_unstemmed PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
title_short PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
title_sort pcsk9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/
https://www.ncbi.nlm.nih.gov/pubmed/36544639
http://dx.doi.org/10.21037/atm-22-4652
work_keys_str_mv AT kongni pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis
AT xuqin pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis
AT cuiwei pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis
AT fengxiaoying pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis
AT gaohuijie pcsk9inhibitorinclisiranfortreatingatherosclerosisviaregulationofendothelialcellpyroptosis